Trial Profile
A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate; Methotrexate
- Indications Joint disorders; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms LITHE
- Sponsors Roche
- 26 Aug 2020 Results of a pooled analysis from twelve phase 3 and 4 clinical trials: ACT-RAY, ACT-STAR, ACT-SURE, ADACTA, AMBITION, BREVACTA, COMP-ACT, LITHE, OPTION, ROSE, SUMMACTA and TOWARD assessing predictors of response, including demographics, disease characteristics at baseline published in the Rheumatology
- 06 Jun 2020 Results of pooled analysis from seven studies (OPTION, RADIATE, TOWARD, LITHE, ACT-RAY, ADACTA and BREVACTA) presented at the 21st Annual Congress of the European League Against Rheumatism.
- 06 Jun 2020 Results of pooled analysis from three phase III studies (OPTION, TOWARD and LITHE) presented at the 21st Annual Congress of the European League Against Rheumatism